fda warning compounded semaglutide october 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Decisions Expected: October 2025
Description
Semaglutide significantly improved RV function, as evidenced by reduced right ventricular systolic pressure (RVSP), hypertrophy index (RV/LV + S), and improved echocardiographic parameters (RVEDA, RVFAC, TAPSE)
Based on treating hundreds of patients with stubborn weight issues, Ive found that the best plateau-breaking strategies are always personalized
Currently, the only version of semaglutide licenced to treat weight loss is Wegovy, which is administered as a once-weekly injection
Conclusion The evolution of weight loss with semaglutide has given millions of people a new sense of hope
